

Purified anti-human VEGFR-3 (FLT-4)

Catalog # / Size: 356201 / 50 µg
356202 / 200 µg

Clone: 9D9F9

Isotype: Mouse IgG1, κ

Immunogen: VEGFR extracellular domain protein


Reactivity: Human

Preparation: The antibody was purified by affinity chromatography.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.5 mg/ml

Storage: The antibody solution should be stored undiluted between 2°C and 8°C.



HUVEC, human endothelial cells were stained with purified VEGFR3 (clone 9D9F9) (filled histogram) or mouse IgG1, κ isotype control (open histogram), followed by anti-mouse IgG PE.

Applications:

Applications: FC - *Quality tested*
IHC - *Reported in the literature*

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Additional reported applications (for relevant formats) include: immunohistochemistry staining of frozen or paraffin embedded sections¹⁻³.

Application References:

1. Jussila L, *et al.* 1998. *Cancer Res.* 58:1599. (IHC)
2. Kilic N, *et al.* 2007. *Blood* 110:4223. (IHC)
3. Folpe A, *et al.* 2000. *Mod. Pathol.* 13:180. (IHC)

Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Fik-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1‐D7), a single transmembrane, helix, and a cytoplasmic region with tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides that remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. Aberrant activation or expression of VEGFR and their ligands has been implicated in tumor angiogenesis, coronary artery disease, diabetic blindness, and other diseases.

Antigen References:

1. Tammela T, *et al.* 2008. *Nature* 454:656.
2. Partanen TA, *et al.* 2000. *FASEB J.* 14:2087.
3. Valtola R, *et al.* 1999. *Am. J. Pathol.* 154:1381.
4. Jussila L, *et al.* 1998. *Cancer Res.* 58:1599.
5. Galland F, *et al.* 1992. *Genomics* 13:475.

Related Products:

Product
 Purified Mouse IgG1, κ Isotype Ctrl
 Cell Staining Buffer
 RBC Lysis Buffer (10X)
 Human TruStain FcX™ (Fc Receptor Blocking Solution)

Clone
 MOPC-21

Application
 FC, ICFC, ICC, IF, IHC, IP, WB
 FC, ICC, ICFC
 FC, ICFC
 FC, ICC, ICFC



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.



*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.